Navigation Links
New Argonne study may shed light on protein-drug interactions
Date:1/15/2008

ecular keys. Even todays introductory biology courses rely on descriptions of protein behavior that require them to swivel and pivot very little as they interact with other biological molecules, according to Makowski. Thats a very powerful image but its not the whole story, he said. Weve learned that proteins in solution can take on an entire ensemble of slightly different structures, and that, for most proteins, this ensemble grows much larger as you go to smaller and smaller concentrations.

Makowski and his colleagues were also surprised to discover that environmental conditions strongly influence which state in this ensemble of conformations a protein prefers to enter. Most of a proteins common configurations have a functional purpose, he said, as it is not likely to twist itself into something completely irrelevant to its function.

For example, one of the five proteins examined in the study, hemoglobin, has two favored conformations: one in which it binds oxygen very readily and one in which it does not. When hemoglobin is placed in a solution that contains a great deal of available oxygen, it spends most of the time in the former state, while if oxygen is not available, it usually flips into the latter. We now know that in dilute solutions, hemoglobin actually can take on both conformations - even in the absence of oxygen, he said.

By keeping all of the environmental factors the same save for the protein concentration in the solution, Makowski and his team discovered another surprising result. Scientists had known for many years that when proteins are too concentrated, they aggregate and fall out of solution. However, biochemists previously had difficulty explaining why a similar effect also occurs in overly dilute solutions.

Proteins have hydrophobic or water-hating core regions that try to avoid touching water if at all possible. Because of this characteristic, proteins will rearrange themselves to protect these r
'/>"/>

Contact: Steve McGregor
smcgregor@anl.gov
630-252-5580
DOE/Argonne National Laboratory
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Argonne National Lab acquires first SiCortex SC5832
2. Argonne helps China create cleaner Beijing for 2008 Olympics
3. Sea otter study reveals striking variability in diets and feeding strategies
4. Study: weight-loss tips differ in African-American, mainstream magazines
5. Study helps explain how allergic reactions are triggered
6. Selective restraints and reduced medication could reduce nursing home falls says 4-year study
7. Study locates cholesterol genes; finds surprises about good, bad cholesterol
8. Study suggests genetic connection between short stature and arthritis
9. Radioactive understudy may aid medical imaging, drug development
10. Surprise -- cholesterol may actually pose benefits, study shows
11. Hybridization partially restores vision in cavefish, NYU study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3